The researchers, who stem from various universities, hospitals and institutions in the U.K., sought to look at antimicrobial resistance from an economics perspective.
They noted the difficulty of modeling the global trajectory of antimicrobial resistance — along with its resulting effects on health and economy — due to various factors such as which drug and pathogen are involved, the mechanism of antibiotic resistance, and the prevalence of that pathogen.
However, researchers said economic policies are necessary to incentivize the introduction of interventions to decrease unnecessary antibiotic use and stimulate more research and development into new antibiotics.
“Rather than taxing the price and letting the market dictate the quantity of antibiotics supplied, an alternative may be to establish a regulatory body that issue prescribers tradable permits and to allow the market to determine the price,” the researchers added. “Such an approach could create a predictable revenue stream through more-foreseeable licensing fees for important antibiotics by decoupling the return on investment from the volume used.”
More articles on clinical leadership & infection control:
Patient gratitude can positively affect care team performance
High flu activity will last several more weeks, CDC says
Congo’s Ebola outbreak surpasses 1,100 cases: 3 updates
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
